Cas:59229-63-9 3,3-Dimethylmorpholine manufacturer & supplier

Chemical Name:3,3-Dimethylmorpholine

CAS.NO:59229-63-9

Synonyms:3,3-Dimethyl-morpholin;Morpholine,3,3-dimethyl;3,3-Dimethyl-morpholine;Morpholine, 3,3-dimethyl-;3,3-Dimethylmorpholine

Molecular Formula:C₆H₁₃NO

Molecular Weight:115.174

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:144.3±15.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.410

PSA:21.26000

Exact Mass:115.099716

LogP:-0.05

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,3-Dimethyl-morpholin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,3-Dimethylmorpholine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,3-Dimethylmorpholine Use and application,3,3-Dimethylmorpholine technical grade,usp/ep/jp grade.

Related News: The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application. 3,3-Dimethylmorpholine manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 3,3-Dimethylmorpholine supplier Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large. 3,3-Dimethylmorpholine vendor Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large. 3,3-Dimethylmorpholine factory The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.